APP and neoplasm: As it was difficult to distinguish the difference in tumor growth inhibiting effect of oAd/APP and oAd/APP+DC at the viral dose (1 × 1010 VP) utilized in Figure 2A, the therapeutic efficacy of the combination therapy utilizing lower viral doses (5 × 107 or 2 × 108 VP) under the same treatment schedule were investigated.